ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
11.31
-0.50 (-4.23%)
At close: Oct 13, 2026, 4:00 PM EDT
11.43
+0.12 (1.06%)
After-hours: Oct 13, 2026, 5:21 PM EDT
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 111 employees as of June 30, 2026. The number of employees decreased by 17 or -13.28% compared to the same quarter last year. That makes ORIC Pharmaceuticals the 30,771st largest employer in the world and 3,951st in the United States.
Employees
111
Change
-17
Growth
-13.28%
Revenue / Employee
n/a
Profits / Employee
-$1,264,423
Market Cap
1.17B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 111 | -17 | -13.28% |
| Mar 31, 2026 | 104 | -18 | -14.75% |
| Dec 31, 2025 | 104 | -11 | -9.57% |
| Sep 30, 2025 | 106 | -6 | -5.36% |
| Jun 30, 2025 | 128 | 21 | 19.63% |
| Mar 31, 2025 | 122 | 20 | 19.61% |
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Sep 30, 2024 | 112 | 19 | 20.43% |
| Jun 30, 2024 | 107 | 18 | 20.22% |
| Mar 31, 2024 | 102 | 14 | 15.91% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Sep 30, 2023 | 93 | 5 | 5.68% |
| Jun 30, 2023 | 89 | 6 | 7.23% |
| Mar 31, 2023 | 88 | 9 | 11.39% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Sep 30, 2022 | 88 | 14 | 18.92% |
| Jun 30, 2022 | 83 | 13 | 18.57% |
| Mar 31, 2022 | 79 | 13 | 19.70% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 465 |
| Syndax Pharmaceuticals | 298 |
| Kardigan | 241 |
| Bicara Therapeutics | 103 |
| Nanobiotix | 100 |
| Taysha Gene Therapies | 99 |
| Vor Biopharma | 76 |
| Savara | 70 |
ORIC News
- 7 days ago - Oric Pharmaceuticals participates in a conference call with JPMorgan - TheFly
- 8 days ago - Oric Pharmaceuticals enters pact with Cancer Research UK to advance ORIC-259 - TheFly
- 8 days ago - ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development - GlobeNewsWire
- 8 days ago - Oric Pharmaceuticals initiated with an Outperform at Leerink - TheFly
- 11 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Oric Pharmaceuticals initiated with a Buy at BTIG - TheFly
- 20 days ago - Oric Pharmaceuticals initiated with a Buy at BTIG - TheFly
- 4 weeks ago - ORIC Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts